Upgrade to SI Premium - Free Trial

AngioDynamics (ANGO)

12.34 +0.41 (3.44%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (7/21/26)

Latest Headlines

AngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes Effect May 28, 2026 1:25 PM - BizWire AngioDynamics to Present at the Goldman Sachs 47th Annual Global Healthcare Conference May 27, 2026 8:30 AM - BizWire Form SCHEDULE 13G/A ANGIODYNAMICS INC Filed by: Point72 Asset Management, L.P. May 15, 2026 4:20 PM - SEC Filing AngioDynamics reports sustained prostate cancer treatment outcomes at 24 months May 13, 2026 9:00 AM - StreetInsider AngioDynamics Announces Two-Year PRESERVE Trial Data Demonstrating Durable NanoKnife IRE System Outcomes in Intermediate-Risk Prostate Cancer May 13, 2026 9:00 AM - BizWire Form 8-K ANGIODYNAMICS INC For: Apr 23 April 23, 2026 7:07 PM - SEC Filing Freedom Broker Starts AngioDynamics (ANGO) at Buy April 6, 2026 9:35 AM - StreetInsider AngioDynamics (ANGO) PT Lowered to $16 at Canaccord April 6, 2026 6:35 AM - StreetInsider Form 10-Q ANGIODYNAMICS INC For: Feb 28 April 2, 2026 1:56 PM - SEC Filing AngioDynamics (ANGO) PT Lowered to $16 at Canaccord April 2, 2026 1:17 PM - StreetInsider Form 8-K ANGIODYNAMICS INC For: Apr 02 April 2, 2026 7:31 AM - SEC Filing AngioDynamics (ANGO) Tops Q3 EPS by 2c ; Offers Guidance April 2, 2026 6:20 AM - StreetInsider AngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued Profitability April 2, 2026 6:00 AM - BizWire AngioDynamics to Present at the 25th Annual Needham Virtual Healthcare Conference March 31, 2026 8:00 AM - BizWire Form SCHEDULE 13G/A ANGIODYNAMICS INC Filed by: VANGUARD GROUP INC March 26, 2026 3:50 PM - SEC Filing AngioDynamics to Report Fiscal 2026 Third Quarter Results on April 2, 2026 March 19, 2026 8:00 AM - BizWire Full Article List